Castle Biosciences (CSTL) Financials

$16.10 +0.21 (+1.32%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$16.11 +0.01 (+0.06%)

As of 05/23/2025 07:59 PM Eastern

Annual Income Statements for Castle Biosciences

This table shows Castle Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	18	-57	-69
Consolidated Net Income / (Loss)	18	-57	-67
Net Income / (Loss) Continuing Operations	18	-57	-67
Total Pre-Tax Income	22	-57	-69
Total Operating Income	8.67	-68	-73
Total Gross Profit	272	175	105
Total Revenue	332	220	137
Operating Revenue	332	220	137
Total Cost of Revenue	60	45	32
Operating Cost of Revenue	60	45	32
Total Operating Expenses	263	243	178
Selling, General & Admin Expense	200	180	143
Research & Development Expense	52	54	45
Amortization Expense	11	9.01	8.27
Other Special Charges / (Income)	0.00	0.00	-18
Total Other Income / (Expense), net	13	11	3.95
Interest Expense	0.58	0.01	0.02
Interest & Investment Income	13	11	3.97
Other Income / (Expense), net	0.56	0.00	0.00
Income Tax Expense	3.32	0.10	-1.77
Basic Earnings per Share	$0.66	($2.14)	($2.58)
Weighted Average Basic Shares Outstanding	27.78M	26.80M	26.05M
Diluted Earnings per Share	$0.62	($2.14)	($2.58)
Weighted Average Diluted Shares Outstanding	29.26M	26.80M	26.05M
Weighted Average Basic & Diluted Shares Outstanding	28.51M	27.45M	26.58M
Cash Dividends to Common per Share	$0.00	$0.00	$0.00

This table shows Castle Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	9.59	2.27	8.92	-2.53	-2.54	-6.87	-19	-29	-22	-20
Consolidated Net Income / (Loss)	9.59	2.27	8.92	-2.53	-2.58	-6.91	-19	-29	-21	-20
Net Income / (Loss) Continuing Operations	9.59	2.27	8.92	-2.53	-2.58	-6.91	-19	-29	-21	-20
Total Pre-Tax Income	7.89	8.28	7.89	-2.49	-2.54	-6.87	-19	-29	-21	-20
Total Operating Income	4.05	5.08	5.01	-5.47	-5.66	-9.64	-21	-32	-23	-22
Total Gross Profit	70	70	72	59	54	50	39	32	29	28
Total Revenue	86	86	87	73	66	61	50	42	38	37
Operating Revenue	86	86	87	73	66	61	50	42	38	37
Total Cost of Revenue	16	16	15	14	12	11	11	10	9.52	8.86
Operating Cost of Revenue	16	16	15	14	12	11	11	10	9.52	8.86
Total Operating Expenses	66	65	67	65	59	60	60	63	52	50
Selling, General & Admin Expense	50	50	51	48	44	45	45	47	38	37
Research & Development Expense	12	12	14	14	13	13	13	14	11	11
Amortization Expense	4.34	2.27	2.25	2.25	2.27	2.27	2.25	2.22	2.22	2.31
Total Other Income / (Expense), net	3.84	3.20	2.87	2.98	3.12	2.77	2.40	2.33	2.27	1.29
Interest Expense	0.09	0.20	0.27	0.01	0.00	0.00	0.00	0.00	0.00	0.01
Interest & Investment Income	3.37	3.40	3.14	3.00	3.12	2.77	2.40	2.34	2.28	1.29
Income Tax Expense	-1.71	6.01	-1.03	0.05	0.04	0.03	0.02	0.01	0.06	0.00
Basic Earnings per Share	$0.35	$0.08	$0.32	($0.09)	($0.08)	($0.26)	($0.70)	($1.10)	($0.78)	($0.77)
Weighted Average Basic Shares Outstanding	27.78M	27.84M	27.65M	27.49M	26.80M	26.83M	26.73M	26.61M	26.05M	26.32M
Diluted Earnings per Share	$0.32	$0.08	$0.31	($0.09)	($0.08)	($0.26)	($0.70)	($1.10)	($0.78)	($0.77)
Weighted Average Diluted Shares Outstanding	29.26M	29.40M	28.74M	27.49M	26.80M	26.83M	26.73M	26.61M	26.05M	26.32M
Weighted Average Basic & Diluted Shares Outstanding	28.51M	28.01M	27.74M	27.61M	27.45M	26.91M	26.81M	26.69M	26.58M	26.35M

This table details how cash moves in and out of Castle Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	21	-24	-207
Net Cash From Operating Activities	65	-5.63	-42
Net Cash From Continuing Operating Activities	65	-5.63	-42
Net Income / (Loss) Continuing Operations	18	-57	-67
Consolidated Net Income / (Loss)	18	-57	-67
Depreciation Expense	16	12	11
Amortization Expense	-6.69	-5.49	-1.37
Non-Cash Adjustments To Reconcile Net Income	51	52	36
Changes in Operating Assets and Liabilities, net	-14	-6.60	-20
Net Cash From Investing Activities	-50	-16	-167
Net Cash From Continuing Investing Activities	-50	-16	-167
Purchase of Property, Plant & Equipment	-28	-14	-5.63
Acquisitions	0.00	0.00	-26
Purchase of Investments	-206	-189	-135
Sale of Property, Plant & Equipment	0.02	0.01	0.20
Sale and/or Maturity of Investments	184	187	0.00
Net Cash From Financing Activities	6.14	-2.30	1.52
Net Cash From Continuing Financing Activities	6.14	-2.30	1.52
Repayment of Debt	-0.10	-0.14	-0.12
Issuance of Debt	10	0.00	0.00
Issuance of Common Equity	2.98	2.71	2.49
Other Financing Activities, net	-6.75	-4.87	-0.86
Cash Interest Paid	0.43	0.01	0.02
Cash Income Taxes Paid	2.50	0.20	0.12

This table details how cash moves in and out of Castle Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	25	9.39	2.62	-16	7.62	-4.65	-19	-8.13	-11	-139
Net Cash From Operating Activities	24	23	24	-6.84	19	5.01	-3.79	-25	-6.00	-5.22
Net Cash From Continuing Operating Activities	24	23	24	-6.84	19	5.01	-3.79	-25	-6.00	-5.22
Net Income / (Loss) Continuing Operations	9.59	2.27	8.92	-2.53	-2.58	-6.91	-19	-29	-21	-20
Consolidated Net Income / (Loss)	9.59	2.27	8.92	-2.53	-2.58	-6.91	-19	-29	-21	-20
Depreciation Expense	5.77	3.54	3.35	3.34	3.22	3.17	3.04	2.89	2.84	2.92
Amortization Expense	-1.61	-1.65	-1.72	-1.70	-1.64	-1.57	-1.05	-1.23	-1.18	-0.18
Non-Cash Adjustments To Reconcile Net Income	11	13	13	13	12	13	12	14	8.59	9.60
Changes in Operating Assets and Liabilities, net	-0.64	5.70	0.03	-19	7.10	-2.68	0.95	-12	4.37	2.69
Net Cash From Investing Activities	5.77	-15	-21	-20	-7.67	-9.71	-15	17	-4.48	-134
Net Cash From Continuing Investing Activities	5.77	-15	-21	-20	-7.67	-9.71	-15	17	-4.48	-134
Purchase of Property, Plant & Equipment	-7.57	-6.38	-5.23	-9.15	-3.79	-2.46	-4.04	-3.34	-1.79	-2.04
Purchase of Investments	-47	-45	-52	-61	-52	-50	-56	-30	-2.88	-132
Sale of Property, Plant & Equipment	0.01	0.00	0.00	0.01	0.00	0.00	0.00	0.01	0.19	0.00
Sale and/or Maturity of Investments	61	37	36	50	49	43	45	50	-	-
Net Cash From Financing Activities	-5.39	0.84	0.04	11	-3.30	0.05	0.23	0.73	-0.75	0.39
Net Cash From Continuing Financing Activities	-5.39	0.84	0.04	11	-3.30	0.05	0.23	0.73	-0.75	0.39
Repayment of Debt	-0.03	-0.02	-0.01	-0.04	-0.04	-0.04	-0.04	-0.04	-0.03	-0.03
Issuance of Common Equity	0.65	0.59	0.66	1.09	0.68	0.34	0.71	0.98	0.68	0.30
Other Financing Activities, net	-6.01	0.28	-0.61	-0.41	-3.94	-0.26	-0.45	-0.22	-1.40	0.12

This table presents Castle Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	531	453	447
Total Current Assets	360	296	292
Cash & Equivalents	120	99	123
Short-Term Investments	173	144	136
Accounts Receivable	51	38	23
Inventories, net	8.14	7.94	3.98
Prepaid Expenses	7.67	6.29	6.21
Plant, Property, & Equipment, net	51	25	14
Total Noncurrent Assets	120	132	141
Noncurrent Note & Lease Receivables	0.92	1.19	1.09
Goodwill	106	117	126
Other Noncurrent Operating Assets	13	14	13
Total Liabilities & Shareholders' Equity	531	453	447
Total Liabilities	75	62	48
Total Current Liabilities	49	48	36
Short-Term Debt	0.28	0.00	-
Accounts Payable	6.90	10	4.73
Accrued Expenses	7.99	7.32	5.26
Current Employee Benefit Liabilities	33	29	24
Other Current Liabilities	1.67	1.14	1.78
Total Noncurrent Liabilities	26	14	12
Long-Term Debt	9.75	0.00	-
Noncurrent Deferred & Payable Income Tax Liabilities	1.61	0.21	0.43
Other Noncurrent Operating Liabilities	15	14	12
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	456	391	399
Total Preferred & Common Equity	456	391	399
Preferred Stock	0.00	0.00	0.00
Total Common Equity	456	391	399
Common Stock	656	610	560
Retained Earnings	-200	-218	-161
Accumulated Other Comprehensive Income / (Loss)	0.23	0.14	-0.38

This table presents Castle Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	515	487	459	436	425	427	458
Total Current Assets	345	320	296	280	269	271	299
Cash & Equivalents	95	86	83	91	96	115	134
Short-Term Investments	185	174	156	139	130	117	132
Accounts Receivable	50	46	43	37	31	28	23
Inventories, net	6.57	8.01	7.65	5.77	6.12	4.52	3.80
Prepaid Expenses	8.15	6.72	6.22	7.10	6.11	6.80	6.80
Plant, Property, & Equipment, net	44	39	33	22	21	18	13
Total Noncurrent Assets	125	128	130	134	136	138	145
Noncurrent Note & Lease Receivables	1.11	1.13	1.06	1.34	1.23	1.22	1.19
Goodwill	111	113	115	120	122	124	130
Other Noncurrent Operating Assets	14	14	14	13	13	12	14
Total Liabilities & Shareholders' Equity	515	487	459	436	425	427	458
Total Liabilities	74	63	56	50	47	42	46
Total Current Liabilities	44	39	32	36	34	30	32
Accounts Payable	6.81	9.54	9.32	6.93	7.14	9.96	5.77
Accrued Expenses	8.07	7.45	6.74	5.90	7.32	5.61	5.11
Current Employee Benefit Liabilities	28	21	15	22	17	13	20
Other Current Liabilities	1.75	1.23	1.19	1.09	1.97	1.78	1.54
Total Noncurrent Liabilities	29	24	24	14	13	12	14
Long-Term Debt	10	10	10	-	-	-	-
Noncurrent Deferred & Payable Income Tax Liabilities	4.22	0.00	0.21	0.44	0.44	0.44	0.61
Other Noncurrent Operating Liabilities	15	14	14	13	12	11	14
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	441	424	402	386	379	385	411
Total Preferred & Common Equity	441	424	402	386	379	385	411
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	441	424	402	386	379	385	411
Common Stock	650	636	623	602	588	575	552
Retained Earnings	-210	-212	-221	-216	-209	-190	-140
Accumulated Other Comprehensive Income / (Loss)	0.47	-0.17	-0.11	-0.07	-0.14	-0.14	-0.19

This table displays calculated financial ratios and metrics derived from Castle Biosciences' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	51.09%	60.38%	45.65%
EBITDA Growth	130.32%	3.99%	-73.65%
EBIT Growth	113.57%	6.70%	-81.78%
NOPAT Growth	115.42%	6.70%	-81.78%
Net Income Growth	131.75%	14.41%	-114.55%
EPS Growth	128.97%	17.05%	-108.06%
Operating Cash Flow Growth	1,252.97%	86.49%	-119.43%
Free Cash Flow Firm Growth	68.82%	49.52%	-4.88%
Invested Capital Growth	16.57%	5.44%	71.15%
Revenue Q/Q Growth	6.47%	14.47%	10.75%
EBITDA Q/Q Growth	225.04%	21.86%	-13.26%
EBIT Q/Q Growth	988.73%	20.17%	-11.75%
NOPAT Q/Q Growth	1,395.68%	20.17%	-11.75%
Net Income Q/Q Growth	200.33%	23.89%	-26.80%
EPS Q/Q Growth	181.82%	24.65%	-25.85%
Operating Cash Flow Q/Q Growth	9.78%	81.38%	-8.38%
Free Cash Flow Firm Q/Q Growth	-8.86%	21.31%	23.24%
Invested Capital Q/Q Growth	0.84%	-5.04%	-3.39%
Profitability Metrics	-	-	-
Gross Margin	81.87%	79.53%	76.64%
EBITDA Margin	5.58%	-27.82%	-46.47%
Operating Margin	2.61%	-30.93%	-53.16%
EBIT Margin	2.78%	-30.93%	-53.16%
Profit (Net Income) Margin	5.49%	-26.15%	-48.99%
Tax Burden Percent	84.61%	100.18%	97.44%
Interest Burden Percent	233.76%	84.39%	94.58%
Effective Tax Rate	15.39%	0.00%	0.00%
Return on Invested Capital (ROIC)	4.57%	-32.96%	-45.81%
ROIC Less NNEP Spread (ROIC-NNEP)	0.43%	-29.03%	-40.33%
Return on Net Nonoperating Assets (RNNOA)	-0.26%	18.42%	29.26%
Return on Equity (ROE)	4.31%	-14.54%	-16.56%
Cash Return on Invested Capital (CROIC)	-10.73%	-38.26%	-98.29%
Operating Return on Assets (OROA)	1.87%	-15.09%	-16.01%
Return on Assets (ROA)	3.71%	-12.76%	-14.76%
Return on Common Equity (ROCE)	4.31%	-14.54%	-16.56%
Return on Equity Simple (ROE_SIMPLE)	4.00%	-14.69%	-16.82%
Net Operating Profit after Tax (NOPAT)	7.34	-48	-51
NOPAT Margin	2.21%	-21.65%	-37.21%
Net Nonoperating Expense Percent (NNEP)	4.15%	-3.94%	-5.49%
Return On Investment Capital (ROIC_SIMPLE)	1.57%	-12.16%	-12.78%
Cost of Revenue to Revenue	18.13%	20.47%	23.36%
SG&A Expenses to Revenue	60.24%	81.97%	104.35%
R&D to Revenue	15.67%	24.40%	32.77%
Operating Expenses to Revenue	79.26%	110.46%	129.81%
Earnings before Interest and Taxes (EBIT)	9.23	-68	-73
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	19	-61	-64
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.64	1.48	1.55
Price to Tangible Book Value (P/TBV)	2.14	2.12	2.27
Price to Revenue (P/Rev)	2.25	2.64	4.53
Price to Earnings (P/E)	40.91	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	2.44%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.68	2.28	2.57
Enterprise Value to Revenue (EV/Rev)	1.40	1.54	2.64
Enterprise Value to EBITDA (EV/EBITDA)	24.99	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	50.22	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	63.16	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	7.14	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.02	0.00	0.00
Long-Term Debt to Equity	0.02	0.00	0.00
Financial Leverage	-0.62	-0.63	-0.73
Leverage Ratio	1.16	1.14	1.12
Compound Leverage Factor	2.72	0.96	1.06
Debt to Total Capital	2.15%	0.00%	0.00%
Short-Term Debt to Total Capital	0.06%	0.00%	0.00%
Long-Term Debt to Total Capital	2.09%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	97.85%	100.00%	100.00%
Debt to EBITDA	0.54	0.00	0.00
Net Debt to EBITDA	-15.27	0.00	0.00
Long-Term Debt to EBITDA	0.53	0.00	0.00
Debt to NOPAT	1.37	0.00	0.00
Net Debt to NOPAT	-38.59	0.00	0.00
Long-Term Debt to NOPAT	1.33	0.00	0.00
Altman Z-Score	6.80	5.59	7.68
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	7.29	6.20	8.09
Quick Ratio	6.97	5.90	7.81
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-17	-55	-109
Operating Cash Flow to CapEx	229.14%	-41.34%	-766.14%
Free Cash Flow to Firm to Interest Expense	-29.85	-5,020.81	-6,436.26
Operating Cash Flow to Interest Expense	112.42	-511.45	-2,450.29
Operating Cash Flow Less CapEx to Interest Expense	63.36	-1,748.55	-2,770.12
Efficiency Ratios	-	-	-
Asset Turnover	0.67	0.49	0.30
Accounts Receivable Turnover	7.42	7.12	6.72
Inventory Turnover	7.49	7.55	10.67
Fixed Asset Turnover	8.68	11.06	11.51
Accounts Payable Turnover	7.01	6.00	8.80
Days Sales Outstanding (DSO)	49.20	51.30	54.28
Days Inventory Outstanding (DIO)	48.73	48.37	34.21
Days Payable Outstanding (DPO)	52.04	60.85	41.49
Cash Conversion Cycle (CCC)	45.89	38.81	47.00
Capital & Investment Metrics	-	-	-
Invested Capital	173	148	141
Invested Capital Turnover	2.07	1.52	1.23
Increase / (Decrease) in Invested Capital	25	7.65	58
Enterprise Value (EV)	463	338	362
Market Capitalization	746	581	620
Book Value per Share	$16.28	$14.54	$15.15
Tangible Book Value per Share	$12.48	$10.18	$10.35
Total Capital	466	391	399
Total Debt	10	0.00	0.00
Total Long-Term Debt	9.75	0.00	0.00
Net Debt	-283	-243	-259
Capital Expenditures (CapEx)	28	14	5.44
Debt-free, Cash-free Net Working Capital (DFCFNWC)	18	4.87	-2.47
Debt-free Net Working Capital (DFNWC)	311	248	256
Net Working Capital (NWC)	311	248	256
Net Nonoperating Expense (NNE)	-11	9.88	16
Net Nonoperating Obligations (NNO)	-283	-243	-259
Total Depreciation and Amortization (D&A)	9.31	6.84	9.18
Debt-free, Cash-free Net Working Capital to Revenue	5.39%	2.22%	-1.80%
Debt-free Net Working Capital to Revenue	93.67%	112.82%	186.92%
Net Working Capital to Revenue	93.58%	112.82%	186.92%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	$0.66	($2.14)	($2.58)
Adjusted Weighted Average Basic Shares Outstanding	27.78M	26.80M	26.05M
Adjusted Diluted Earnings per Share	$0.62	($2.14)	($2.58)
Adjusted Weighted Average Diluted Shares Outstanding	29.26M	26.80M	26.05M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	28.51M	27.45M	26.58M
Normalized Net Operating Profit after Tax (NOPAT)	7.34	-48	-64
Normalized NOPAT Margin	2.21%	-21.65%	-46.56%
Pre Tax Income Margin	6.49%	-26.10%	-50.28%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	15.99	-6,179.73	-4,285.59
NOPAT to Interest Expense	12.71	-4,325.81	-2,999.91
EBIT Less CapEx to Interest Expense	-33.07	-7,416.82	-4,605.41
NOPAT Less CapEx to Interest Expense	-36.35	-5,562.90	-3,319.74
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Castle Biosciences' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	30.54%	39.50%	73.53%	73.59%	72.47%	66.15%	43.92%	56.55%	53.11%	57.66%
EBITDA Growth	301.40%	186.75%	134.62%	87.17%	80.76%	57.25%	-1,327.40%	-33.51%	-54.34%	-75.26%
EBIT Growth	171.58%	152.69%	123.69%	82.64%	75.22%	55.24%	-432.79%	-28.58%	-50.50%	-82.29%
NOPAT Growth	224.37%	120.62%	138.28%	82.64%	75.22%	55.24%	-432.79%	-28.58%	-50.50%	-82.29%
Net Income Growth	471.71%	132.86%	147.50%	91.32%	87.49%	65.90%	-1,039.38%	-18.60%	-220.65%	-71.73%
EPS Growth	500.00%	130.77%	144.29%	91.82%	89.74%	66.23%	-1,066.67%	-13.40%	-212.00%	-63.83%
Operating Cash Flow Growth	31.09%	365.64%	733.86%	73.13%	409.78%	195.94%	57.94%	-18.71%	-115.75%	14.82%
Free Cash Flow Firm Growth	-69.16%	19.99%	21.93%	63.65%	84.40%	84.53%	81.12%	42.48%	14.37%	-120.27%
Invested Capital Growth	16.57%	9.78%	13.67%	13.17%	5.44%	7.27%	3.21%	40.24%	71.15%	199.68%
Revenue Q/Q Growth	0.62%	-1.40%	19.22%	10.37%	7.52%	22.65%	19.27%	9.65%	3.59%	6.24%
EBITDA Q/Q Growth	17.72%	5.02%	273.29%	5.99%	49.30%	58.09%	35.80%	-41.01%	-12.65%	-1,299.63%
EBIT Q/Q Growth	-20.26%	1.34%	191.61%	3.31%	41.31%	54.44%	32.88%	-38.06%	-6.02%	-442.33%
NOPAT Q/Q Growth	253.99%	-75.46%	248.03%	3.31%	41.31%	54.44%	32.88%	-38.06%	-6.02%	-442.33%
Net Income Q/Q Growth	322.65%	-74.56%	452.01%	1.78%	62.64%	63.23%	35.70%	-41.64%	-1.82%	-1,128.70%
EPS Q/Q Growth	300.00%	-74.19%	444.44%	-12.50%	69.23%	62.86%	36.36%	-41.03%	-1.30%	-1,183.33%
Operating Cash Flow Q/Q Growth	4.40%	-2.75%	451.10%	-136.77%	270.85%	232.38%	85.12%	-323.98%	-14.85%	41.96%
Free Cash Flow Firm Q/Q Growth	-41.61%	9.29%	36.28%	-106.66%	33.02%	11.49%	70.34%	11.30%	33.57%	-8.00%
Invested Capital Q/Q Growth	0.84%	-1.68%	0.56%	16.93%	-5.04%	1.81%	0.11%	8.94%	-3.39%	-2.05%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	81.25%	81.80%	83.31%	80.96%	81.21%	81.59%	77.94%	75.78%	75.17%	76.06%
EBITDA Margin	9.51%	8.13%	7.63%	-5.25%	-6.16%	-13.07%	-38.23%	-71.03%	-55.23%	-50.79%
Operating Margin	4.69%	5.92%	5.76%	-7.50%	-8.56%	-15.68%	-42.20%	-74.99%	-59.55%	-58.19%
EBIT Margin	4.69%	5.92%	5.76%	-7.50%	-8.56%	-15.68%	-42.20%	-74.99%	-59.55%	-58.19%
Profit (Net Income) Margin	11.11%	2.65%	10.25%	-3.47%	-3.90%	-11.23%	-37.45%	-69.47%	-53.78%	-54.71%
Tax Burden Percent	121.62%	27.40%	113.11%	101.81%	101.53%	100.47%	100.09%	100.05%	100.28%	100.00%
Interest Burden Percent	194.69%	163.06%	157.34%	45.49%	44.91%	71.30%	88.68%	92.60%	90.05%	94.02%
Effective Tax Rate	-21.62%	72.60%	-13.11%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	11.81%	3.09%	11.45%	-8.06%	-9.12%	-13.98%	-32.80%	-60.93%	-51.32%	-51.96%
ROIC Less NNEP Spread (ROIC-NNEP)	10.04%	2.74%	10.08%	-8.63%	-9.67%	-13.91%	-31.21%	-58.19%	-49.75%	-50.32%
Return on Net Nonoperating Assets (RNNOA)	-6.24%	-1.66%	-5.97%	5.05%	6.14%	8.65%	19.44%	38.69%	36.09%	38.46%
Return on Equity (ROE)	5.58%	1.44%	5.48%	-3.01%	-2.98%	-5.33%	-13.36%	-22.25%	-15.23%	-13.50%
Cash Return on Invested Capital (CROIC)	-10.73%	-9.67%	-19.53%	-30.34%	-38.26%	-46.56%	-48.18%	-76.13%	-98.29%	-146.97%
Operating Return on Assets (OROA)	3.17%	3.89%	3.63%	-4.25%	-4.18%	-6.74%	-16.00%	-26.20%	-17.94%	-16.15%
Return on Assets (ROA)	7.49%	1.74%	6.46%	-1.97%	-1.90%	-4.82%	-14.20%	-24.27%	-16.20%	-15.19%
Return on Common Equity (ROCE)	5.58%	1.44%	5.48%	-3.01%	-2.98%	-5.33%	-13.36%	-22.25%	-15.23%	-13.50%
Return on Equity Simple (ROE_SIMPLE)	0.00%	1.38%	-0.73%	-7.65%	0.00%	-19.57%	-23.46%	-18.62%	0.00%	-12.87%
Net Operating Profit after Tax (NOPAT)	4.93	1.39	5.67	-3.83	-3.96	-6.75	-15	-22	-16	-15
NOPAT Margin	5.71%	1.62%	6.52%	-5.25%	-5.99%	-10.97%	-29.54%	-52.49%	-41.69%	-40.73%
Net Nonoperating Expense Percent (NNEP)	1.77%	0.35%	1.37%	0.56%	0.55%	-0.06%	-1.59%	-2.74%	-1.58%	-1.64%
Return On Investment Capital (ROIC_SIMPLE)	1.06%	-	-	-	-1.01%	-	-	-	-4.00%	-
Cost of Revenue to Revenue	18.75%	18.20%	16.69%	19.04%	18.79%	18.41%	22.06%	24.22%	24.83%	23.94%
SG&A Expenses to Revenue	57.89%	58.87%	58.72%	66.46%	66.68%	72.56%	89.12%	111.24%	100.23%	98.96%
R&D to Revenue	13.64%	14.37%	16.25%	18.92%	19.65%	21.02%	26.54%	34.24%	29.50%	29.47%
Operating Expenses to Revenue	76.56%	75.88%	77.55%	88.46%	89.77%	97.27%	120.14%	150.76%	134.72%	134.25%
Earnings before Interest and Taxes (EBIT)	4.05	5.08	5.01	-5.47	-5.66	-9.64	-21	-32	-23	-22
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	8.21	6.97	6.64	-3.83	-4.07	-8.04	-19	-30	-21	-19
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.64	1.79	1.42	1.48	1.48	1.17	0.97	1.57	1.55	1.67
Price to Tangible Book Value (P/TBV)	2.14	2.39	1.93	2.07	2.12	1.70	1.43	2.31	2.27	2.44
Price to Revenue (P/Rev)	2.25	2.54	2.09	2.38	2.64	2.36	2.19	3.97	4.53	5.54
Price to Earnings (P/E)	40.91	131.56	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	2.44%	0.76%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	2.68	3.04	2.02	2.12	2.28	1.43	0.92	2.43	2.57	2.89
Enterprise Value to Revenue (EV/Rev)	1.40	1.67	1.22	1.46	1.54	1.16	0.84	2.44	2.64	3.39
Enterprise Value to EBITDA (EV/EBITDA)	24.99	91.40	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	50.22	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	63.16	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	7.14	8.82	8.62	28.27	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.02	0.02	0.02	0.02	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.02	0.02	0.02	0.02	0.00	0.00	0.00	0.00	0.00	0.00
Financial Leverage	-0.62	-0.60	-0.59	-0.59	-0.63	-0.62	-0.62	-0.66	-0.73	-0.76
Leverage Ratio	1.16	1.15	1.14	1.12	1.14	1.12	1.10	1.11	1.12	1.08
Compound Leverage Factor	2.26	1.87	1.79	0.51	0.51	0.80	0.98	1.03	1.01	1.02
Debt to Total Capital	2.15%	2.22%	2.31%	2.42%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.06%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	2.09%	2.22%	2.31%	2.42%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	97.85%	97.78%	97.69%	97.58%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	0.54	1.76	-1.08	-0.28	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to EBITDA	-15.27	-47.30	26.84	6.53	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.53	1.76	-1.08	-0.28	0.00	0.00	0.00	0.00	0.00	0.00
Debt to NOPAT	1.37	-17.69	-0.91	-0.34	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt to NOPAT	-38.59	476.49	22.64	7.81	0.00	0.00	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	1.33	-17.69	-0.91	-0.34	0.00	0.00	0.00	0.00	0.00	0.00
Altman Z-Score	6.76	7.23	6.39	6.90	6.04	5.75	4.92	8.85	8.05	9.26
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.29	7.78	8.12	9.25	6.20	7.70	7.98	8.99	8.09	9.37
Quick Ratio	6.97	7.45	7.75	8.82	5.90	7.34	7.62	8.62	7.81	9.04
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-20	-14	-15	-24	-12	-17	-20	-66	-74	-112
Operating Cash Flow to CapEx	322.29%	366.14%	459.12%	-74.72%	490.42%	204.32%	-93.90%	-763.25%	-374.77%	-256.46%
Free Cash Flow to Firm to Interest Expense	-213.39	-68.97	-56.61	-1,713.19	-5,802.80	-8,663.50	-6,525.30	-16,497.85	-18,600.10	-18,665.03
Operating Cash Flow to Interest Expense	264.84	116.11	88.88	-488.21	9,293.50	2,506.00	-1,262.00	-6,359.75	-1,500.00	-870.67
Operating Cash Flow Less CapEx to Interest Expense	182.66	84.40	69.52	-1,141.57	7,398.50	1,279.50	-2,606.00	-7,193.00	-1,900.25	-1,210.17
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.67	0.66	0.63	0.57	0.49	0.43	0.38	0.35	0.30	0.28
Accounts Receivable Turnover	7.42	7.15	7.44	7.12	7.12	6.42	6.21	6.39	6.72	5.98
Inventory Turnover	7.49	9.15	7.38	8.01	7.55	8.79	8.35	10.55	10.67	8.77
Fixed Asset Turnover	8.68	9.36	9.72	9.80	11.06	10.87	10.56	11.02	11.51	11.29
Accounts Payable Turnover	7.01	8.22	6.26	5.05	6.00	6.63	7.61	5.46	8.80	6.35
Days Sales Outstanding (DSO)	49.20	51.06	49.05	51.26	51.30	56.88	58.74	57.11	54.28	61.01
Days Inventory Outstanding (DIO)	48.73	39.90	49.46	45.59	48.37	41.51	43.70	34.59	34.21	41.62
Days Payable Outstanding (DPO)	52.04	44.42	58.35	72.26	60.85	55.07	47.98	66.84	41.49	57.50
Cash Conversion Cycle (CCC)	45.89	46.54	40.16	24.60	38.81	43.32	54.46	24.86	47.00	45.13
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	173	171	174	173	148	156	153	153	141	145
Invested Capital Turnover	2.07	1.91	1.76	1.54	1.52	1.27	1.11	1.16	1.23	1.28
Increase / (Decrease) in Invested Capital	25	15	21	20	7.65	11	4.77	44	58	97
Enterprise Value (EV)	463	521	351	367	338	223	141	372	362	420
Market Capitalization	746	791	601	596	581	453	366	604	620	686
Book Value per Share	$16.28	$15.90	$15.35	$14.64	$14.54	$14.39	$14.19	$14.49	$15.15	$15.65
Tangible Book Value per Share	$12.48	$11.92	$11.27	$10.46	$10.18	$9.93	$9.62	$9.82	$10.35	$10.69
Total Capital	466	451	434	412	391	386	379	385	399	411
Total Debt	10	10	10	10	0.00	0.00	0.00	0.00	0.00	0.00
Total Long-Term Debt	9.75	10	10	10	0.00	0.00	0.00	0.00	0.00	0.00
Net Debt	-283	-270	-250	-229	-243	-230	-226	-232	-259	-266
Capital Expenditures (CapEx)	7.56	6.37	5.23	9.15	3.79	2.45	4.03	3.33	1.60	2.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)	18	21	21	25	4.87	14	9.83	8.90	-2.47	1.49
Debt-free Net Working Capital (DFNWC)	311	300	281	264	248	243	235	241	256	267
Net Working Capital (NWC)	311	300	281	264	248	243	235	241	256	267
Net Nonoperating Expense (NNE)	-4.66	-0.88	-3.25	-1.30	-1.38	0.16	3.97	7.14	4.64	5.17
Net Nonoperating Obligations (NNO)	-283	-270	-250	-229	-243	-230	-226	-232	-259	-266
Total Depreciation and Amortization (D&A)	4.16	1.89	1.63	1.64	1.58	1.61	1.99	1.66	1.66	2.74
Debt-free, Cash-free Net Working Capital to Revenue	5.39%	6.63%	7.39%	9.81%	2.22%	7.05%	5.87%	5.85%	-1.80%	1.20%
Debt-free Net Working Capital to Revenue	93.67%	96.34%	97.69%	105.22%	112.82%	126.71%	140.48%	158.29%	186.92%	216.16%
Net Working Capital to Revenue	93.58%	96.34%	97.69%	105.22%	112.82%	126.71%	140.48%	158.29%	186.92%	216.16%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.35	$0.08	$0.32	($0.09)	($0.08)	($0.26)	($0.70)	($1.10)	($0.78)	($0.77)
Adjusted Weighted Average Basic Shares Outstanding	27.78M	27.84M	27.65M	27.49M	26.80M	26.83M	26.73M	26.61M	26.05M	26.32M
Adjusted Diluted Earnings per Share	$0.32	$0.08	$0.31	($0.09)	($0.08)	($0.26)	($0.70)	($1.10)	($0.78)	($0.77)
Adjusted Weighted Average Diluted Shares Outstanding	29.26M	29.40M	28.74M	27.49M	26.80M	26.83M	26.73M	26.61M	26.05M	26.32M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	28.51M	28.01M	27.74M	27.61M	27.45M	26.91M	26.81M	26.69M	26.58M	26.35M
Normalized Net Operating Profit after Tax (NOPAT)	2.84	3.56	3.51	-3.83	-3.96	-6.75	-15	-22	-16	-15
Normalized NOPAT Margin	3.28%	4.14%	4.03%	-5.25%	-5.99%	-10.97%	-29.54%	-52.49%	-42.24%	-41.02%
Pre Tax Income Margin	9.14%	9.65%	9.06%	-3.41%	-3.84%	-11.18%	-37.42%	-69.44%	-53.63%	-54.71%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	44.02	25.27	18.56	-390.79	-2,829.00	-4,820.00	-7,052.33	-7,880.50	-5,708.00	-3,589.33
NOPAT to Interest Expense	53.54	6.92	21.00	-273.55	-1,980.30	-3,374.00	-4,936.63	-5,516.35	-3,995.60	-2,512.53
EBIT Less CapEx to Interest Expense	-38.15	-6.44	-0.80	-1,044.14	-4,724.00	-6,046.50	-8,396.33	-8,713.75	-6,108.25	-3,928.83
NOPAT Less CapEx to Interest Expense	-28.63	-24.79	1.64	-926.91	-3,875.30	-4,600.50	-6,280.63	-6,349.60	-4,395.85	-2,852.03
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Castle Biosciences' Financials

When does Castle Biosciences's financial year end?

According to the most recent income statement we have on file, Castle Biosciences' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Castle Biosciences' net income changed over the last 2 years?

Castle Biosciences' net income appears to be on a downward trend, with a most recent value of $18.25 million in 2024, falling from -$67.14 million in 2022. The previous period was -$57.47 million in 2023. See where experts think Castle Biosciences is headed by visiting Castle Biosciences' forecast page.

What is Castle Biosciences's operating income?

Castle Biosciences's total operating income in 2024 was $8.67 million, based on the following breakdown:

Total Gross Profit: $271.86 million
Total Operating Expenses: $263.19 million

How has Castle Biosciences revenue changed over the last 2 years?

Over the last 2 years, Castle Biosciences' total revenue changed from $137.04 million in 2022 to $332.07 million in 2024, a change of 142.3%.

How much debt does Castle Biosciences have?

Castle Biosciences' total liabilities were at $75.40 million at the end of 2024, a 21.5% increase from 2023, and a 56.5% increase since 2022.

How much cash does Castle Biosciences have?

In the past 2 years, Castle Biosciences' cash and equivalents has ranged from $98.84 million in 2023 to $122.95 million in 2022, and is currently $119.71 million as of their latest financial filing in 2024.

How has Castle Biosciences' book value per share changed over the last 2 years?

Over the last 2 years, Castle Biosciences' book value per share changed from 15.15 in 2022 to 16.28 in 2024, a change of 7.5%.

Related Companies

This page (NASDAQ:CSTL) was last updated on 5/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Castle Biosciences (CSTL) Financials

Frequently Asked Questions About Castle Biosciences' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Castle Biosciences (CSTL) Financials

Annual Income Statements for Castle Biosciences

Quarterly Income Statements for Castle Biosciences

Annual Cash Flow Statements for Castle Biosciences

Quarterly Cash Flow Statements for Castle Biosciences

Annual Balance Sheets for Castle Biosciences

Quarterly Balance Sheets for Castle Biosciences

Annual Metrics And Ratios for Castle Biosciences

Quarterly Metrics And Ratios for Castle Biosciences

Frequently Asked Questions About Castle Biosciences' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools